Is Neurocrine Biosciences, Inc (NASDAQ: NBIX) Still On The Rise?

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.

Stocks Info

This NASDAQ-listed company operates within the Drug Manufacturers – Specialty & Generic industry segment, falling under the Healthcare sector. The current market capitalization of Neurocrine Biosciences, Inc is $14.12B. A total of 0.99 million shares were traded on the day, compared to an average of 981.77K shares.

In the most recent transaction, Delaet Ingrid sold 272 shares of NBIX for 138.10 per share on Dec 31 ’24. After the transaction, the Chief Regulatory Officer now owns 2,507 company shares. In a previous transaction on Dec 31 ’24, INGRID DELAET bought 272 shares at 137.06 per share.

Among the insiders who sold shares, Delaet Ingrid disposed of 1,091 shares on Dec 17 ’24 at a per-share price of $135.00. This resulted in the Chief Regulatory Officer holding 2,507 shares of NBIX after the transaction. In another insider transaction, INGRID DELAET bought 1,091 shares at $133.05 per share on Dec 17 ’24.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, NBIX has a high of $157.98 and a low of $110.95.

As of this writing, NBIX has an earnings estimate of $1.93 per share for the current quarter. EPS was calculated based on a consensus of 14.0 estimates, with a high estimate of $2.51 per share and a lower estimate of $0.5.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. NBIX’s latest balance sheet shows that the firm has $711.30M in Cash & Short Term Investments as of fiscal 2021. There were $440.40M in debt and $245.80M in liabilities at the time. Its Book Value Per Share was $26.87, while its Total Shareholder’s Equity was $1.37B.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NBIX is Buy with a score of 4.62.

Most Popular

Related Posts